Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

May 7, 2018 Issue

09619-cover-cart.jpg

May 7, 2018 Cover

Volume 96, Issue 19

CAR T-cell therapy works wonders for some cancer patients. For others, it is a death sentence. To make the revolutionary therapy work for more people, scientists must devise better ways to control it

Cover:A cartoon of CAR t cells.

Credit: Yang H. Ku/C&EN/Shutterstock

Full Article
Volume 96 | Issue 19

All Issues

Quote of the Week

“Incremental research doesn’t grow the company by much.”

Ulrich Küsthardt, chief innovation officer , Evonik

Controlling CAR-T: How scientists plan to make the engineered T cell therapy safer, and work for more cancers

CAR T-cell therapy works wonders for some cancer patients. For others, it is a death sentence. To make the revolutionary therapy work for more people, scientists must devise better ways to control it

  • Evonik keeps the faith in long-term research

    German chemical maker seeks to balance technical support and basic R&D that can open new markets

  • Chemistry education moves from classroom to escape room

    Chemistry teachers turn to puzzle-based activity to keep high school students engaged 

  • Career Ladder: Yun He

    Opportunities in academia and industry call chemist from China to the U.S.—and back again

ADVERTISEMENT
image name
Energy Storage

New battery could serve the grid

Manganese-hydrogen design boasts high capacity, long life, and the promise of low cost

ADVERTISEMENT
ADVERTISEMENT